A newly published peer-reviewed study in Diabetes Care examines why tirzepatide — the active ingredient in Mounjaro and Zepbound — may be more effective than semaglutide-based drugs like Ozempic and Wegovy. The answer, researchers suggest, lies in tirzepatide's unique ability to activate two distinct hormone receptors rather than one.
The Science Behind the Dual-Action Difference
Most GLP-1 medications, including semaglutide (Ozempic, Wegovy), work by mimicking a single gut hormone called glucagon-like peptide-1, which helps regulate blood sugar and appetite. Tirzepatide goes further. According to the Diabetes Care publication, tirzepatide is a dual incretin receptor agonist, meaning it activates both the GLP-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR) simultaneously. The study describes tirzepatide as "the most effective drug to date" in the incretin-based pharmacology space.
GIP — glucose-dependent insulinotropic polypeptide — is a gut hormone that has historically received less attention than GLP-1. This new research highlights its clinical importance, suggesting its role alongside GLP-1 may be key to tirzepatide's outsized results in treating both type 2 diabetes and obesity.
What Researchers Still Don't Know
Despite tirzepatide's impressive track record, the study notes an important gap in scientific understanding: the relative contributions of GIPR and GLP-1R activity to tirzepatide's clinical effects have not yet been established. In other words, scientists know the dual mechanism works — they're still working out exactly how much each receptor is responsible for the drug's benefits. This is an active area of research with significant implications for future drug development.
Key takeaway: Tirzepatide (Mounjaro, Zepbound) targets two incretin receptors — GLP-1R and GIPR — while semaglutide (Ozempic, Wegovy) targets only GLP-1R. A new Diabetes Care study identifies this dual action as a likely explanation for tirzepatide's superior potency, though the exact contribution of each receptor is still under investigation.
What This Means for Patients
If you're currently taking Ozempic or Wegovy and wondering whether you should switch to Mounjaro or Zepbound, this research provides important scientific context — but it isn't a prescription recommendation. The choice between medications depends on many individual factors, including your diagnosis, insurance coverage, tolerance of side effects, and your prescriber's clinical judgment. What the science does affirm is that the additional GIP receptor engagement in tirzepatide is not a marketing claim — it is a pharmacologically distinct mechanism with real clinical relevance.
What to Watch Next
Researchers are expected to continue untangling the separate roles of GIP and GLP-1 in metabolic health. Understanding which receptor drives which benefit could eventually lead to even more targeted therapies — or help explain why some patients respond better to one class of medication than another. The growing scientific focus on GIPR also opens the door to future drug candidates that may refine or build on tirzepatide's dual-action approach.
Frequently Asked Questions
As the science on dual incretin receptor agonism continues to evolve, the best way to understand what it means for your specific situation is to speak directly with your prescriber or a qualified healthcare professional who knows your full medical history.
- Peer-reviewed journal article, 'Clinical Potential of GIP in Type 2 Diabetes and Obesity,' Diabetes Care, date not specified in source material.